An international biopharmaceutical company focused on research, development and commercial use of prescription drugs in key therapeutic areas, such as oncology, cardiology, diabetes mellitus, respiratory, inflammatory and autoimmune diseases, as well as in neurology. It is registered in more than 100 countries of the world. Its innovative drugs are used by millions of patients.
Russia is one of the priority markets for the company. About 40 AstraZeneca original drugs are registered in the Russian Federation.
AstraZeneca decided to implement an investment project to build a production facility in Russia in 2008. The construction of a pharmaceutical plant in the Kaluga region has been initiated in 2011.
The opening took place on October 20, 2015. The total investment exceeded $224 million. Commercial production began in the 1st quarter of 2016. The design capacity of the enterprise is about 40 million packages, or 850 million tablets per year. The plant produces about 30 AstraZeneca products.
The Kaluga branch of AstraZeneca complies with international GMP standards and LEAN rules, and takes into account the requirements of labor protection, safety, and environmental protection.
Address: Borovsk district, Vorsino Industrial Park, 1st Vostochny proezd, land plot 8